bioRxiv · 10.64898/2026.05.08.723607
Selective Elimination of TP53 Mutant Cells by Transcript-Activated Chromatin Shredding
Abstract
Genetic mutations that drive cancer often occur in tumor suppressor proteins, including the p53 transcription factor which is altered in [~]40-50% of cases1,2. However, current therapies fail to target most such mutations because the mutant proteins typically lack defined drug-binding pockets, and restoring the endogenous function has proven challenging. Here, we programmed CRISPR-Cas12a2, an RNA-guided nuclease with trans-nucleolytic cleavage activities3,4, to selectively kill cancer cells by targeting cancer-specific transcripts. This approach eliminates cells by inducing trans chromatin cleavage, triggering DNA damage and cell death. Unlike existing methods, RNA-guided Cas12a2 senses cellular RNA signatures to shred chromatin, enabling precise targeting of undruggable mutations. Transcript-activated chromatin shredding provides an innovative paradigm to develop precision disease treatments for undruggable targets.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Zeng, J., Cheng, Z., Chen, H., Thompson, J., Crosby, K. T., Hang, H., Ngo, W., Xia, C., Rosas-Rivera, D., Kang, M. H., Mao, Y., Lee, G., Diffley, J. F. X., Song, Y., Qiu, L., Krah, N. M., Murthy, N., Jackson, R. N., Liu, Y., Ashworth, A., Doudna, J. A.. 2026-05-09. Selective Elimination of TP53 Mutant Cells by Transcript-Activated Chromatin Shredding. https://doi.org/10.64898/2026.05.08.723607
Cite the original work for its findings. Save a collection to share your selection of sources.